CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 63 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $345,044 | -25.0% | 267,476 | 0.0% | 0.00% | – |
Q2 2023 | $460,059 | +13.9% | 267,476 | 0.0% | 0.00% | – |
Q1 2023 | $403,889 | -43.6% | 267,476 | -40.3% | 0.00% | – |
Q4 2022 | $716,724 | +120.5% | 447,952 | +100.0% | 0.00% | – |
Q3 2022 | $325,000 | -20.7% | 223,976 | 0.0% | 0.00% | – |
Q2 2022 | $410,000 | -87.2% | 223,976 | -81.3% | 0.00% | – |
Q1 2022 | $3,200,000 | -73.0% | 1,198,682 | -56.2% | 0.00% | -100.0% |
Q4 2021 | $11,862,000 | -42.3% | 2,739,544 | -32.1% | 0.00% | 0.0% |
Q3 2021 | $20,548,000 | -29.7% | 4,036,937 | -12.6% | 0.00% | -50.0% |
Q2 2021 | $29,223,000 | +12.6% | 4,616,562 | +37.4% | 0.00% | +100.0% |
Q1 2021 | $25,964,000 | +93.3% | 3,358,865 | +63.8% | 0.00% | 0.0% |
Q4 2020 | $13,431,000 | -6.0% | 2,050,597 | -4.6% | 0.00% | 0.0% |
Q3 2020 | $14,293,000 | -21.9% | 2,149,254 | -2.1% | 0.00% | 0.0% |
Q2 2020 | $18,290,000 | +141.6% | 2,195,649 | +122.5% | 0.00% | 0.0% |
Q1 2020 | $7,570,000 | -7.9% | 986,948 | -0.3% | 0.00% | 0.0% |
Q4 2019 | $8,223,000 | -27.7% | 989,570 | -35.8% | 0.00% | 0.0% |
Q3 2019 | $11,370,000 | -41.5% | 1,540,689 | -11.1% | 0.00% | 0.0% |
Q2 2019 | $19,449,000 | -13.6% | 1,733,453 | -17.2% | 0.00% | -50.0% |
Q1 2019 | $22,516,000 | -3.2% | 2,094,485 | +36.0% | 0.00% | 0.0% |
Q4 2018 | $23,253,000 | -36.6% | 1,539,950 | -22.3% | 0.00% | -33.3% |
Q3 2018 | $36,658,000 | -6.3% | 1,981,550 | +15.7% | 0.00% | 0.0% |
Q2 2018 | $39,138,000 | +19.3% | 1,712,121 | +48.5% | 0.00% | 0.0% |
Q1 2018 | $32,805,000 | +42.3% | 1,152,958 | +5.6% | 0.00% | +50.0% |
Q4 2017 | $23,047,000 | +48.5% | 1,091,816 | +27.8% | 0.00% | +100.0% |
Q3 2017 | $15,521,000 | +124.5% | 854,018 | +91.3% | 0.00% | 0.0% |
Q2 2017 | $6,914,000 | +42.5% | 446,315 | +58.8% | 0.00% | – |
Q1 2017 | $4,852,000 | +60.3% | 280,973 | +2.0% | 0.00% | – |
Q4 2016 | $3,027,000 | -28.7% | 275,483 | +1.7% | 0.00% | – |
Q3 2016 | $4,248,000 | +63.4% | 270,887 | +6.4% | 0.00% | – |
Q2 2016 | $2,599,000 | +119.9% | 254,501 | +177.3% | 0.00% | – |
Q1 2016 | $1,182,000 | -16.8% | 91,777 | +34.8% | 0.00% | – |
Q4 2015 | $1,421,000 | – | 68,079 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Burrage Capital Management LLC | 476,110 | $3,956,000 | 2.65% |
MPM BioImpact LLC | 855,437 | $7,109,000 | 2.52% |
Exane Asset Management | 87,876 | $730,250,000 | 0.90% |
Congress Park Capital LLC | 94,661 | $787,000 | 0.58% |
Perceptive Advisors | 3,253,923 | $27,040,000 | 0.54% |
BVF INC/IL | 766,148 | $6,367,000 | 0.48% |
RTW INVESTMENTS, LP | 1,039,593 | $8,639,000 | 0.33% |
EcoR1 Capital, LLC | 410,000 | $3,407,000 | 0.31% |
DAFNA Capital Management LLC | 100,000 | $831,000 | 0.28% |
HARBOURVEST PARTNERS LLC | 79,193 | $658,000 | 0.27% |